Edition:
United States

Karo Pharma AB (KARO.ST)

KARO.ST on Stockholm Stock Exchange

31.10SEK
23 Feb 2018
Change (% chg)

-1.65kr (-5.04%)
Prev Close
32.75kr
Open
32.80kr
Day's High
32.85kr
Day's Low
30.65kr
Volume
1,265,374
Avg. Vol
332,958
52-wk High
44.27kr
52-wk Low
24.31kr

Latest Key Developments (Source: Significant Developments)

Karo Pharma AB Q4 Adjusted EBITDA Rises To SEK 41.8 Mln
Thursday, 22 Feb 2018 02:00am EST 

Feb 22 (Reuters) - Karo Pharma Ab ::Q4 NET SALES SEK 238.7 MILLION VERSUS SEK 96.5 MILLION YEAR AGO.Q4 ADJUSTED EBITDA SEK 41.8 MILLION VERSUS SEK 28.9 MILLION YEAR AGO.  Full Article

Karo Pharma Rights Issue Subscribed To 170 Percent
Thursday, 4 Jan 2018 02:00am EST 

Jan 4 (Reuters) - KARO PHARMA AB ::RIGHTS ISSUE SUBSCRIBED TO 170 PERCENT WITH PROCEEDS AT ABOUT SEK 794.3 MILLION BEFORE ISSUE COSTS.  Full Article

Karo Pharma: New Issue To Provide Up To SEK 794.3 Ml‍n Before Issue Costs
Friday, 8 Dec 2017 10:30am EST 

Dec 8 (Reuters) - Karo Pharma Ab ::SAYS NEW ISSUE TO PROVIDE UP TO SEK 794.3 ML‍N BEFORE ISSUE COSTS.  Full Article

Karo Pharma Chairman Called For Inquiry For Inside Trading
Thursday, 30 Nov 2017 02:55am EST 

Nov 30 (Reuters) - Karo Pharma Ab ::CHAIRMAN CALLED IN TO INQUIRY FROM POLICE FOR INSIDE TRADING.BOARD CONCLUDES THE THAT CHAIRMAN HAS ACTED CORRECTLY AND DID NOTHING WRONG, AS PER ITS INVESTIGATION.  Full Article

Karo Pharma signs agreement with Marinomed Biotech
Monday, 27 Nov 2017 02:00am EST 

Nov 27 (Reuters) - Karo Pharma Ab ::KARO PHARMA ANNOUNCES AGREEMENT WITH THE AUSTRIAN PHARMACEUTICAL COMPANY MARINOMED BIOTECH AG.‍WILL MARKET A PATENTED PRODUCT FOR COMMON COLD & FLU SYMPTOMS IN SWEDEN, NORWAY AND FINLAND.​.‍AGREEMENT IS LONG TERM (10 YEARS).​.  Full Article

Karo Pharma to carry out new issue
Wednesday, 8 Nov 2017 02:00am EST 

Nov 8 (Reuters) - KARO PHARMA AB ::TO CARRY OUT NEW ISSUE WITH PROCEEDS AT ABOUT SEK 800 MILLION BEFORE ISSUE COSTS IF FULLY SUBSCRIBED.  Full Article

Karo Pharma Q3 EBITDA sharply up yr/yr​
Thursday, 2 Nov 2017 03:00am EDT 

Nov 2 (Reuters) - Karo Pharma Ab :Says ‍net sales amounted to MSEK 418.9 (250.8), whereof Q3 MSEK 137.1 (85.2)​.Says ‍EBITDA amounted to MSEK 127.5 (22.8), whereof Q3 MSEK 34.0 (10.2)​.  Full Article

Karo Pharma Q3 EBITDA up at SEK ‍34.0​ mln
Thursday, 2 Nov 2017 03:00am EDT 

Nov 2 (Reuters) - KARO PHARMA AB ::Q3 NET SALES SEK ‍137.1​ MILLION VERSUS SEK 85.2 MILLION YEAR AGO.Q3 EBITDA SEK ‍34.0​ MILLION VERSUS SEK 10.2 MILLION YEAR AGO.  Full Article

Karo Pharma owns 97 pct in Weifa upon completion of voluntary offer
Friday, 6 Oct 2017 08:30am EDT 

Oct 6 (Reuters) - KARO PHARMA AB :KARO PHARMA AB COMPLETES VOLUNTARY OFFER FOR WEIFA ASA.‍KARO PHARMA NOW HOLDS 97.21% OF SHARES AND VOTING RIGHTS IN WEIFA.​.  Full Article

Karo Pharma AB says received acceptances for the voluntary offer to acquire all shares in Weifa ASA
Tuesday, 3 Oct 2017 12:00pm EDT 

Oct 3 (Reuters) - Karo Pharma AB -:Expiration of voluntary offer period for Weifa ASA - acquisition successful with acceptances at +97,1 %.Karo Pharma AB says ‍conditions for completion of voluntary offer have been met​.‍Following settlement of voluntary offer, Karo Pharma intends to initiate a compulsory acquisition of remaining outstanding shares of Weifa​.  Full Article

BRIEF-Karo Pharma AB Q4 Adjusted EBITDA Rises To SEK 41.8 Mln

* Q4 NET SALES SEK 238.7 MILLION VERSUS SEK 96.5 MILLION YEAR AGO

No consensus analysis data available.